Joshua Kilgore1, Amanda L Jackson2, Leslie H Clark2, Hui Guo3, Lu Zhang3, Hannah M Jones2, Timothy P Gilliam2, Paola A Gehrig4, Chunxiao Zhou4, Victoria L Bae-Jump4. 1. Division of Gynecologic Oncology, University of North Carolina at Chapel HillChapel Hill, NC. USA; Current address: Houston Methodist Gynecologic Oncology AssociatesHouston, TX. USA. 2. Division of Gynecologic Oncology, University of North Carolina at Chapel Hill Chapel Hill, NC. USA. 3. Division of Gynecologic Oncology, University of North Carolina at Chapel HillChapel Hill, NC. USA; Department of Gynecologic Oncology, Shandong Cancer Hospital & Institute, Jinan UniversityJinan, PR China. 4. Division of Gynecologic Oncology, University of North Carolina at Chapel HillChapel Hill, NC. USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel HillChapel Hill, NC. USA.
Abstract
OBJECTIVE: Biguanides are anti-diabetic drugs that are thought to have anti-tumorigenic effects. Most pre-clinical studies have focused on metformin for cancer treatment and prevention; however, buformin may be potentially more potent than metformin. Given this, our goal was to evaluate the effects of buformin on cell growth, adhesion and invasion in endometrial cancer cell lines. METHODS: The ECC-1 and Ishikawa endometrial cancer cell lines were used. Cell proliferation was assessed by MTT assay. Apoptosis and cell cycle analysis was performed by FITC Annexin V assay and propidium iodide staining, respectively. Adhesion was analyzed using the laminin adhesion assay. Invasion was assessed using the transwell invasion assay. The effects of buformin on the AMPK/mTOR pathway were determined by Western immunoblotting. RESULTS: Buformin and metformin inhibited cell proliferation in a dose-dependent manner in both endometrial cancer cell lines. IC50s were 1.4-1.6 mM for metformin and 8-150 μM for buformin. Buformin induced cell cycle G1 phase arrest in the ECC-1 cells and G2 phase arrest in the Ishikawa cells. For both ECC-1 and Ishikawa cells, treatment with buformin resulted in induction of apoptosis, reduction in adhesion and invasion, activation of AMPK and inhibition of phosphorylated-S6. Buformin potentiated the anti-proliferative effects of paclitaxel in both cell lines. CONCLUSION: Buformin has significant anti-proliferative and anti-metastatic effects in endometrial cancer cells through modulation of the AMPK/mTOR pathway. IC50 values were lower for buformin than metformin, suggesting that buformin may be more potent for endometrial cancer treatment and worthy of further investigation.
OBJECTIVE:Biguanides are anti-diabetic drugs that are thought to have anti-tumorigenic effects. Most pre-clinical studies have focused on metformin for cancer treatment and prevention; however, buformin may be potentially more potent than metformin. Given this, our goal was to evaluate the effects of buformin on cell growth, adhesion and invasion in endometrial cancer cell lines. METHODS: The ECC-1 and Ishikawa endometrial cancer cell lines were used. Cell proliferation was assessed by MTT assay. Apoptosis and cell cycle analysis was performed by FITCAnnexin V assay and propidium iodide staining, respectively. Adhesion was analyzed using the laminin adhesion assay. Invasion was assessed using the transwell invasion assay. The effects of buformin on the AMPK/mTOR pathway were determined by Western immunoblotting. RESULTS:Buformin and metformin inhibited cell proliferation in a dose-dependent manner in both endometrial cancer cell lines. IC50s were 1.4-1.6 mM for metformin and 8-150 μM for buformin. Buformin induced cell cycle G1 phase arrest in the ECC-1 cells and G2 phase arrest in the Ishikawa cells. For both ECC-1 and Ishikawa cells, treatment with buformin resulted in induction of apoptosis, reduction in adhesion and invasion, activation of AMPK and inhibition of phosphorylated-S6. Buformin potentiated the anti-proliferative effects of paclitaxel in both cell lines. CONCLUSION:Buformin has significant anti-proliferative and anti-metastatic effects in endometrial cancer cells through modulation of the AMPK/mTOR pathway. IC50 values were lower for buformin than metformin, suggesting that buformin may be more potent for endometrial cancer treatment and worthy of further investigation.
Authors: Emily M Ko; Paige Walter; Leslie Clark; Amanda Jackson; Jason Franasiak; Corey Bolac; Laura Havrilesky; Angeles Alvarez Secord; Dominic T Moore; Paola A Gehrig; Victoria L Bae-Jump Journal: Gynecol Oncol Date: 2014-04 Impact factor: 5.482
Authors: Vladimir N Anisimov; Lev M Berstein; Irina G Popovich; Mark A Zabezhinski; Peter A Egormin; Margarita L Tyndyk; Ivan V Anikin; Anna V Semenchenko; Anatoli I Yashin Journal: Ann N Y Acad Sci Date: 2005-12 Impact factor: 5.691
Authors: Ziwei Fang; Jiandong Wang; Leslie H Clark; Wenchuan Sun; Yajie Yin; Weimin Kong; Stuart R Pierce; Lindsay West; Stephanie A Sullivan; Arthur-Quan Tran; Varun V Prabhu; Chunxiao Zhou; Victoria Bae-Jump Journal: Am J Cancer Res Date: 2018-08-01 Impact factor: 6.166
Authors: Sonia A Ronchetti; María Teresa L Pino; Georgina Cordeiro; Sabrina N Bollani; Analía G Ricci; Beatriz H Duvilanski; Jimena P Cabilla Journal: Sci Rep Date: 2019-10-15 Impact factor: 4.379